四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00460 四环医药

重阳节翌日休市 10-16 16:08:16

0.705

+0.010

+1.44%

最高0.720	最低0.695	成交量1,795万
今开0.700	昨收0.695	日振幅3.60%
总市值64.27亿	流通市值64.27亿	总股本91.16亿
成交额1,270万	换手率0.20%	流通股本91.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.705,"timestamp":1792138096002,"preClose":0.695,"halted":0,"volume":17952334,"delay":0,"changeRate":0.014388489208633108,"floatShares":9116000000,"shares":9116000000,"eps":0.0197,"marketStatus":"重阳节翌日休市","change":0.01,"latestTime":"10-16 16:08:16","open":0.7,"high":0.72,"low":0.695,"amount":12695070,"amplitude":0.035971,"askPrice":0.705,"askSize":713000,"bidPrice":0.695,"bidSize":538000,"shortable":3,"etf":0,"ttmEps":0.038573,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1288195200000,"exchange":"SEHK","adjPreClose":0.695,"dividendRate":0.015882,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.9491306321754404,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2675961573","title":"四环医药抢先押注“全长三螺旋”，一场重组人III型胶原蛋白稀缺原料的卡位战","url":"https://stock-news.laohu8.com/highlight/detail?id=2675961573","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675961573?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:51","pubTimestamp":1791939099,"startTime":"0","endTime":"0","summary":"提前锁定了一张下一轮竞争的门票。","market":"us","thumbnail":"https://img7.gelonghui.com/column/10.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/10.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6975430","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["00460","BK1191","BK1593","BK1515","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673406077","title":"四环医药(00460.HK)战略投资汉腾生物，完善再生医美全产业链布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2673406077","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673406077?lang=zh_cn&edition=full","pubTime":"2026-10-08 20:54","pubTimestamp":1791464080,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00460","BK1191","BK1593","BK1515","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141924092","title":"四环医药（00460）子公司完成对汉腾生物战略投资 加速再生医美全产业链布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1141924092","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141924092?lang=zh_cn&edition=full","pubTime":"2026-10-08 20:52","pubTimestamp":1791463928,"startTime":"0","endTime":"0","summary":"2026年10月8日，四环医药控股集团有限公司发布自愿性公告称，其旗下渼颜空间生物科技（吉林）有限公司已完成对广州汉腾生物科技有限公司的战略股权投资，并计划围绕汉腾生物的全长三螺旋重组人III型胶原蛋白原料开展联合商业化合作。1) 获取完整三螺旋结构的全长重组人III型胶原蛋白稳定供应，突破行业片段化胶原及动物源胶原的原料瓶颈；","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673734038","title":"创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673734038","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673734038?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:54","pubTimestamp":1791251688,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，歌礼制药-B 涨11.78%，再鼎医药涨6.55%，金斯瑞生物科技涨5.30%，晶泰控股涨4.40%，中国生物制药涨3.96%，三生制药涨3.41%，药明生物涨3.16%，康方生物涨3.11%，云顶新耀涨3.10%，四环医药涨2.82%。2026ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK4588","09926","LU0029874061.USD","LU0348766576.USD","LU2476274308.USD","LU0823426308.USD","LU0320764599.SGD","IE00BZ08YT58.USD","BK1141","LU0348827113.USD","01672","LU0052750758.USD","01177","LU0516423091.SGD","LNGR","BK4139","MEDX","LU0348735423.USD","LU0359201612.USD","01548","LU1242518931.SGD","01952","BK1161","LU0348784397.USD","IBBQ","LU0211977185.USD","159992","BK1191","00460","LU0417516902.SGD","09688","02269","01530","LU2778985437.USD","LU0708995153.HKD","BK1515","IE00BPRC5H50.USD","HK0000306701.USD","KURE","LU0516422366.SGD","02228","LU0140636845.USD","LU0320764243.SGD","06978","BK1574","01477","LU0029874905.USD","SG9999002463.SGD","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705076","title":"四环医药(00460)：水光针(商品名：冻妍)新增规格获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705076","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673705076?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:04","pubTimestamp":1791191081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药 发布公告，本集团旗下渼颜空间生物科技(吉林)有限公司自主研发的注射用透明质酸钠复合溶液五个新增规格已正式获得中国国家药品监督管理局批准上市。本次新增规格获批为该产品上市后的重要进展，进一步夯实本集团在轻医美水光赛道的产品布局与竞争力。目前，渼颜空间在全球落成三个生产基地，具有完善的品质管理体系，并对产品的全生命周期实施有效风险管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","00460","BK1593","BK1600","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107235859","title":"四环医药（00460）水光针“凍妍”再添五款新规格获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1107235859","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107235859?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:02","pubTimestamp":1791190943,"startTime":"0","endTime":"0","summary":"2026年10月5日，四环医药公告称，旗下渼颜空间生物科技（吉林）有限公司自主研发的注射用透明质酸钠复合溶液新增0.75mL╱支、1.25mL╱支、1.75mL╱支、2.25mL╱支、2.75mL╱支共五个规格，已获得中国国家药品监督管理局批准上市。至此，“凍妍”已形成涵盖0.5mL至3.0mL区间的十二项剂量谱系。公司指出，水光针作为轻医美核心品类，具有较高复购属性。四环医药表示，本次获批的梯度化规格可为同类产品的研发与迭代提供参考，有助于促进行业规范化、精细化发展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152330279","title":"四环医药更新2026年9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1152330279","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152330279?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:15","pubTimestamp":1790928948,"startTime":"0","endTime":"0","summary":"四环医药控股集团有限公司于2026年10月2日发布截至2026年9月30日的证券变动月报表。公告显示，公司本月未发生新增股份发行或股份购回等交易活动，股本结构保持稳定。截至2026年9月30日，公司已发行股份及库存股份总数维持在9,329,999,206股，较上月无变化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669170708","title":"【券商聚焦】广发证券首予四环医药（00460）买入评级 指医美与创新药进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669170708","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669170708?lang=zh_cn&edition=full","pubTime":"2026-09-23 14:04","pubTimestamp":1790143494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 广发证券发布研报指，四环医药 早期起家于心脑血管等仿制药业务，在医药集采期主动求变，积极向医美与创新药业务转型，2025年利润扭亏为盈，26H1归母净利达2.2亿元，进入业绩兑现阶段。渠道端，至26H1医美渠道覆盖终端机构超9000家，于行业承压下实现医美收入6.9亿元，同增18.5%，税前利润3.4亿元，同增10.9%。公司加速剥离非核心资产，创新药减亏与医美利润兑现进一步改善报表质量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992305","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","01776","IBBQ","LNGR","159992","KCE","MEDX","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669509139","title":"医美概念股多股上扬 三生制药（01530）涨5.71%、四环医药（00460）涨4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669509139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669509139?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:09","pubTimestamp":1789956581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股多股上扬，截至发稿，山东新华制药股份 涨10.81%，三生制药涨5.71%，四环医药涨4.17%，昊海生物科技涨3.82%，复星医药涨3.12%，现代牙科涨3.10%，时代天使涨2.25%。消息面上，国金证券表示，医美板块下游连锁景气回暖，上游平台化逻辑有望兑现，建议关注上游头部连锁化机构、需求扩容下具备强渠道能力的上游平台化标的。看好布局差异化赛道的上游医美产品厂商及满足医美新场景需求的下游医美机构。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK1161","BK1600","01530","03600","00719","06826","BK1583","HK0000165453.HKD","06699","BK1587","BK1191","00460","02196","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169352351","title":"四环医药2026年中期营收11.61亿元，经营利润3.13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169352351","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169352351?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:57","pubTimestamp":1789549054,"startTime":"0","endTime":"0","summary":"四环医药发布2026年中期业绩。报告期内，公司实现营收11.61亿元，同比上升1.3%。本期毛利为6.82亿元，上年同期为7.57亿元，毛利率为58.7%。经营利润达3.13亿元，上年同期约2.64亿元，同比增长18.6%。经营活动现金流为-0.92亿元，上一年同期为-0.95亿元。分销开支2.17亿元，同比下降6.1%，占营收比例约18.71%；行政开支2.07亿元，同比下降2.2%；研发投入1.06亿元，同比下降30.9%，占营收比例约9.09%。公司医疗美容业务收入6.93亿元，同比增长18.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"四环医药2026年中期营收11.61亿元，经营利润3.13亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664386607","title":"港股异动 | 四环医药(00460)午前涨近4% 轩竹生物与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664386607?lang=zh_cn&edition=full","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1600","00460","BK1515","VXUS","BK1593","BK1191","BK4588","KCAI","02575","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162680804","title":"四环医药(00460)子公司轩竹生物携手Innobic　独家推进吡洛西利片进入泰国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1162680804","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162680804?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:21","pubTimestamp":1788427316,"startTime":"0","endTime":"0","summary":"2026年9月3日，四环医药控股集团有限公司发布自愿公告称，其非全资附属公司轩竹生物科技股份有限公司已与泰国制药公司Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd签署有关吡洛西利片的三方商业协议，协议有效期至2036年6月30日。根据协议，轩竹生物向Innobic（亚洲）及早安国际授予吡洛西利片在泰国市场的独家商业化权利，涵盖进口、推广、营销、要约销售、销售及经销等环节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385197","title":"四环医药(00460.HK)授出合共1.16亿份股份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385197","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664385197?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:01","pubTimestamp":1788267673,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","BK1191","BK1600","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136509054","title":"四环医药8月股份变动月报表：回购1000万股纳入库存，总股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1136509054","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136509054?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:33","pubTimestamp":1788251596,"startTime":"0","endTime":"0","summary":"四环医药于2026年9月1日发布截至2026年8月31日的股份变动月报表。公告显示，公司法定/注册股本维持为100,000,000,000股，每股面值为港币0.01元，注册股本总额为港币1,000,000,000，与上月持平。2026年8月27日，公司以平均每股港币0.8111买回10,000,000股并将其转为库存股份，回购的股份暂未注销。本次交易完成后，公司流通股份减少至9,115,988,206股，库存股份增加至214,011,000股，总股份数仍为9,329,999,206股，股本总数维持不变。公告称，公司已符合香港联交所相关上市规则的公众持股量要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012004","title":"四环医药(00460.HK)委任车雨轩为非执行董事 双轮驱动战略见效中期盈利翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012004","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012004?lang=zh_cn&edition=full","pubTime":"2026-08-29 19:13","pubTimestamp":1788002032,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","BK1593","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171641075","title":"四环医药(00460)回购1,000万股　耗资约811.1万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171641075","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171641075?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:06","pubTimestamp":1787832388,"startTime":"0","endTime":"0","summary":"2026年8月27日，四环医药控股集团有限公司公告称，公司已依据股东于2025年6月6日股东周年大会授权的一般回购授权，于2026年8月27日从公开市场回购股份。— 回购规模：共计回购股份10,000,000股，占公司已发行股份总数约0.1096%。公告同时披露，公司2026年上半年实现营收11.61亿元人民币，同比增长1.3%；净利润2.12亿元人民币，同比增长221%。董事会表示，当前股价未能充分反映公司内在价值，股份回购能够展现对未来业务发展的信心，并维护全体股东权益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662591706","title":"四环医药(00460.HK)8月27日耗资811.1万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662591706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662591706?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:39","pubTimestamp":1787827197,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00460","BK1600","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167377227","title":"四环医药8月27日回购1000万股，耗资约811.10万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167377227","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167377227?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:36","pubTimestamp":1787826967,"startTime":"0","endTime":"0","summary":"四环医药于2026年8月27日发布翌日披露报表，公告公司当日通过香港联交所场内完成股份回购事宜，回购股份数量为1,000万股，约占回购前已发行股本的0.1096%。本次回购的最高回购价为每股0.82港元，最低回购价为每股0.77港元，合计支付约811.10万港元。根据公告，四环医药股份回购授权于2026年6月26日获股东大会批准，批准可回购股份总数为912,598,820股，此次回购后，已回购股份数为1,000万股，占授权总数的约0.1096%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"四环医药8月27日回购1000万股，耗资约811.10万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760937","title":"四环医药：缪瑰丽辞任执行董事 宋晓弥接任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760937","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662760937?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:51","pubTimestamp":1787723460,"startTime":"0","endTime":"0","summary":"8月26日，四环医药（00460）发布公告，公司执行董事、副行政总裁及首席财务官缪瑰丽因专注个人事业发展辞任。同时，公司委任车雨轩为非执行董事及董事会风险管理委员会委员，委任宋晓弥为首席财务官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854445757.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854445757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1600","BK1191","BK1593","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760602","title":"四环医药：上半年归母净利润2.25亿元 同比增119%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760602","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662760602?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:51","pubTimestamp":1787723460,"startTime":"0","endTime":"0","summary":"8月26日，四环医药（00460）发布2026年中期业绩，公司归母净利润达2.25亿元，同比增119%，主要由于医美业务收益增加。公司总收益约为11.61亿元，同比上升约1.3%。其中，医美业务的收益约为6.93亿元，同比上升约18.5%，主要得益于核心产品乐提葆?的稳定增长及再生类医美产品的持续放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854446288.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854446288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.007},{"period":"3month","weight":-0.1802},{"period":"6month","weight":-0.4635},{"period":"1year","weight":-0.5303},{"period":"ytd","weight":-0.4198}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家主要从事研发、制造及销售医药产品和医美产品的投资控股公司。该公司通过三个分部运营其业务。医美产品分部包括填充类、塑形类、支撑类、补充类、光电设备类、体雕类、皮肤管理类及其他以及提供轻医美综合解决方案。创新药及其他药品分部从事研发及商业化糖尿病、乳腺癌、消化、肿瘤及非酒精性脂肪型肝炎等疾病领域的创新药。仿制药分部从事包括克林澳等仿制药的生产和销售。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119713},{"month":2,"riseRate":0.5,"avgChangeRate":0.000651},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.032043},{"month":4,"riseRate":0.533333,"avgChangeRate":0.038601},{"month":5,"riseRate":0.4,"avgChangeRate":0.003084},{"month":6,"riseRate":0.533333,"avgChangeRate":-0.005353},{"month":7,"riseRate":0.6,"avgChangeRate":0.012776},{"month":8,"riseRate":0.466667,"avgChangeRate":-0.024743},{"month":9,"riseRate":0.2,"avgChangeRate":-0.043907},{"month":10,"riseRate":0.533333,"avgChangeRate":0.025465},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008336},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017751}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}